India’s Biocon Biologics says the European Medicines Agency’s recent endorsement of the Inpremzia biosimilar fast-acting human insulin rival to Actrapid represents a “milestone” for the company as it continues its efforts to expand access to insulin products.
In late February, the EMA’s committee for medicinal products for human use issued a positive opinion recommending that Inpremzia –...






